NAPLEX Quiz: Goals Safety And Effectiveness

What this quiz covers

This quiz focuses on Goals Safety And Effectiveness, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Continue lithium and ibuprofen; symptoms are expected early in therapy and will self-resolve
2. Recognize probable lithium toxicity; stop NSAID use, hold lithium, and arrange urgent medical evaluation with repeat levels and renal monitoring (correct answer)
3. Increase lithium to 900 mg twice daily to achieve faster mood stabilization
4. Switch sertraline to fluoxetine 20 mg daily to reduce tremor and confusion

Explanation: Person-centered assessment requires recognizing drug-induced toxicity from pharmacokinetic interactions, particularly with narrow therapeutic index drugs. The key patient-specific factors are lithium toxicity symptoms (nausea, tremor, confusion) with elevated lithium level (1.9 mEq/L) and increased creatinine, precipitated by NSAID use which reduces renal lithium clearance. Recognizing toxicity and stopping the NSAID while holding lithium pending urgent evaluation (choice B) is critical to prevent progression to severe toxicity including seizures or coma. Continuing current therapy (A) ignores clear toxicity signs. Increasing lithium (C) would worsen potentially life-threatening toxicity. Changing antidepressants (D) doesn't address the primary lithium-NSAID interaction causing toxicity. The clinical pearl is that NSAIDs significantly increase lithium levels by reducing renal clearance; always screen for NSAID use (prescription and OTC) in lithium-treated patients and educate about avoiding NSAIDs or using alternatives like acetaminophen when possible.

Question 2

1. Continue current regimen; falls are most likely due to age and should be managed with a cane only
2. Deprescribe diphenhydramine and taper diazepam; consider nonpharmacologic sleep/anxiety strategies and safer alternatives (correct answer)
3. Increase diazepam to 10 mg three times daily to reduce anxiety-related dizziness
4. Switch diphenhydramine to hydroxyzine 50 mg nightly because it has fewer anticholinergic effects

Explanation: Person-centered assessment in older adults requires identifying and eliminating high-risk medications that increase fall risk and cognitive impairment. The key patient-specific factors are recent falls in an 81-year-old taking multiple Beers Criteria medications: diphenhydramine (anticholinergic), diazepam (long-acting benzodiazepine), and oxybutynin (anticholinergic). Deprescribing diphenhydramine and tapering diazepam (choice B) addresses the primary fall risk factors while transitioning to safer alternatives and non-pharmacologic approaches. Continuing current therapy (A) ignores preventable medication-related falls. Increasing diazepam (C) would worsen sedation and fall risk. Switching to hydroxyzine (D) replaces one sedating antihistamine with another without addressing the benzodiazepine or cumulative anticholinergic burden. The clinical pearl is that polypharmacy review in older adults should prioritize deprescribing CNS-active drugs, particularly anticholinergics and benzodiazepines, which synergistically increase fall risk; always taper benzodiazepines gradually to prevent withdrawal.

Question 3

1. Start metformin 500 mg twice daily and titrate; add basal insulin glargine 10 units nightly due to A1c ≥9% (correct answer)
2. Start glyburide 10 mg twice daily as first-line therapy because it lowers A1c rapidly
3. Start metformin 500 mg once daily only and defer any titration or additional therapy for 6 months
4. Start pioglitazone 45 mg daily as monotherapy because renal function is normal

Explanation: Person-centered assessment for newly diagnosed diabetes requires considering glycemic burden, symptoms, and evidence-based treatment algorithms. The key patient-specific factor is the significantly elevated A1c of 9.6% with symptomatic hyperglycemia (polyuria and polydipsia), indicating the need for combination therapy. Starting metformin with planned titration plus basal insulin (choice A) follows current guidelines for symptomatic patients with A1c ≥9%, addressing both insulin resistance and deficiency. Starting glyburide at maximum dose (B) risks hypoglycemia and weight gain without addressing the magnitude of hyperglycemia. Metformin monotherapy without titration (C) is insufficient for this degree of hyperglycemia and delays necessary intensification. Pioglitazone monotherapy (D) causes weight gain and edema, is less effective than metformin, and is not first-line therapy. The clinical pearl is that patients presenting with A1c ≥9% and symptoms often require dual therapy initiation, with metformin plus basal insulin being the preferred approach to rapidly achieve glycemic control while minimizing hypoglycemia risk.

Question 4

1. Sertraline use with warfarin increases bleeding risk; stop sertraline immediately
2. Ibuprofen use with warfarin and supratherapeutic INR increases bleeding risk; discontinue ibuprofen and address INR (correct answer)
3. Acetaminophen PRN may reduce warfarin effect; increase warfarin dose
4. Amiodarone reduces warfarin effect; increase warfarin dose by 50%

Explanation: Person-centered assessment and treatment planning for anticoagulation involve identifying drug interactions and monitoring parameters to prevent bleeding or thrombotic events. The key patient-specific factor is the supratherapeutic INR combined with ibuprofen use, which potentiates warfarin's anticoagulant effect and increases bleeding risk in a patient with CKD. Discontinuing ibuprofen and addressing the INR is the best choice for immediate safety, as NSAIDs like ibuprofen are contraindicated with warfarin due to additive bleeding risks. Sertraline with warfarin may increase bleeding but is not the primary issue here and doesn't require immediate cessation; acetaminophen may slightly affect warfarin but increasing dose is inappropriate; amiodarone potentiates rather than reduces warfarin effect, so increasing dose is incorrect. In anticoagulation management, regularly review concurrent medications for interactions and adjust based on INR trends. Prioritize non-NSAID analgesics in patients on warfarin to enhance safety.

Question 5

1. Pioglitazone may worsen fluid retention in HFrEF; discontinue pioglitazone and select an alternative diabetes agent (correct answer)
2. Metformin causes edema; discontinue metformin and start glyburide
3. Carvedilol causes fluid retention; discontinue carvedilol abruptly
4. Spironolactone causes edema; increase spironolactone to 50 mg daily

Explanation: Person-centered assessment and treatment planning in heart failure require evaluating medications for potential exacerbation of fluid retention and optimizing therapy for comorbidities. The key patient-specific factor is the presence of HFrEF with new edema, where pioglitazone's fluid retention side effect can worsen heart failure symptoms. Discontinuing pioglitazone and selecting an alternative diabetes agent is the best choice for safety and effectiveness, as thiazolidinediones are contraindicated in symptomatic heart failure. Metformin does not typically cause edema and glyburide increases hypoglycemia risk; carvedilol should not be discontinued abruptly due to rebound risks; spironolactone helps reduce edema and increasing it without assessment is inappropriate. In patients with heart failure and diabetes, prefer agents like SGLT2 inhibitors for dual benefits. Always monitor weight and symptoms to guide de-escalation of offending agents.

Question 6

1. Continue albuterol PRN only; add montelukast 10 mg PO daily as monotherapy
2. Start low-dose inhaled corticosteroid (e.g., budesonide 180 mcg 2 puffs twice daily) and continue albuterol PRN (correct answer)
3. Start salmeterol inhaler monotherapy twice daily and stop albuterol
4. Start prednisone 60 mg PO daily indefinitely

Explanation: Person-centered assessment and treatment planning in asthma involve stepping up therapy based on symptom control and guidelines. The key patient-specific factor is frequent albuterol use indicating poor control, requiring addition of a controller. Starting low-dose ICS is the best choice for effectiveness and safety in moderate persistent asthma. Montelukast monotherapy is insufficient; salmeterol monotherapy risks asthma death; indefinite prednisone has significant side effects. In asthma management, follow GINA guidelines for step therapy. Educate on inhaler technique and trigger avoidance for better outcomes.

Question 7

1. Reduced levothyroxine absorption due to concurrent iron/calcium; separate levothyroxine from cations and administer on empty stomach (correct answer)
2. Alendronate reduces iron absorption; stop alendronate
3. Ferrous sulfate causes hyperthyroidism; reduce levothyroxine dose
4. Calcium carbonate increases levothyroxine absorption; increase calcium dose

Explanation: Person-centered assessment and treatment planning involve tailoring medication regimens to individual patient needs, considering comorbidities, drug interactions, and administration practices to optimize safety and efficacy. In this case, the key patient-specific factor is the concurrent administration of levothyroxine with iron and calcium supplements along with food, which impairs levothyroxine absorption. The best choice is A because separating levothyroxine from cations like iron and calcium, and administering it on an empty stomach, directly addresses the reduced absorption leading to suboptimal hypothyroidism control, enhancing safety and effectiveness. Choice B is incorrect as alendronate does not significantly reduce iron absorption, and stopping it overlooks the primary issue while potentially compromising osteoporosis management. Choices C and D are less optimal; C wrongly attributes hyperthyroidism to ferrous sulfate when the patient is hypothyroid, and D incorrectly states that calcium increases levothyroxine absorption when it actually decreases it. A key clinical pearl is to always review medication timing and food interactions in patients with hypothyroidism, as evidence shows that cations and food can reduce levothyroxine bioavailability by up to 40%. This framework emphasizes patient education on proper administration to prevent subtherapeutic levels and promote adherence in evidence-based practice.

Question 8

1. Monitor for genital mycotic infections and volume depletion; counsel on hydration and sick-day management (correct answer)
2. Monitor for agranulocytosis; obtain CBC weekly for 6 months
3. Monitor for ototoxicity; obtain baseline and periodic audiograms
4. Monitor for QT prolongation; obtain ECG monthly

Explanation: Person-centered assessment and treatment planning in diabetes therapy emphasize monitoring for class-specific adverse effects like those of SGLT2 inhibitors. The key patient-specific factor is symptoms of polyuria and thirst, indicating potential volume depletion from empagliflozin's diuretic effect. Monitoring for genital infections and volume depletion with counseling is the best choice for safety, aligning with SGLT2 inhibitor risks. Agranulocytosis monitoring is for other classes like clozapine; ototoxicity is for aminoglycosides; monthly ECGs are unnecessary for empagliflozin. In SGLT2 therapy, educate on hydration and sick-day rules to prevent dehydration. Assess renal function periodically to guide continuation.

Question 9

1. Start glyburide 2.5 mg PO daily with breakfast
2. Start metformin 500 mg PO twice daily with meals and titrate as tolerated (correct answer)
3. Start insulin glargine 10 units subcutaneously nightly as monotherapy
4. Start pioglitazone 45 mg PO daily

Explanation: Person-centered assessment and treatment planning in type 2 diabetes involve tailoring therapy to individual patient preferences, comorbidities, and goals while prioritizing safety and efficacy. The key patient-specific factors here include the preference for oral medication, desire to avoid hypoglycemia, normal renal function, and comorbidities like hypertension and dyslipidemia. Metformin is the best choice as it is the first-line oral agent for type 2 diabetes with a low risk of hypoglycemia, proven cardiovascular benefits, and suitability given normal eGFR. Glyburide is less optimal due to higher hypoglycemia risk, especially in older adults; insulin glargine as monotherapy is injectable and not preferred when orals are desired; pioglitazone may worsen dyslipidemia and cause fluid retention. In similar scenarios, always assess for contraindications like renal impairment before initiating metformin and monitor A1c for effectiveness. Emphasize lifestyle modifications alongside pharmacotherapy for optimal diabetes management.

Question 10

1. Continue chlorthalidone and add potassium chloride 20 mEq PO daily; recheck potassium in 1–2 weeks (correct answer)
2. Increase chlorthalidone to 50 mg PO daily to correct potassium
3. Stop chlorthalidone and start furosemide 40 mg PO twice daily
4. Add digoxin 0.25 mg PO daily for cramps

Explanation: Person-centered assessment and treatment planning for hypertension side effects involve addressing electrolyte imbalances from diuretics. The key patient-specific factor is hypokalemia causing muscle cramps post-chlorthalidone initiation. Adding potassium supplementation with monitoring is the best choice for safety and continuation of therapy. Increasing chlorthalidone worsens hypokalemia; switching to furosemide may not improve BP control; adding digoxin is inappropriate. In thiazide therapy, routinely check electrolytes and supplement as needed. Educate on potassium-rich foods to prevent recurrence.

Question 11

1. Start rivaroxaban 15 mg PO twice daily for 21 days then 20 mg PO daily without renal considerations
2. Start apixaban 10 mg PO twice daily for 7 days then 5 mg PO twice daily
3. Start enoxaparin 1 mg/kg subcutaneously every 12 hours without dose adjustment
4. Start unfractionated heparin bridge to warfarin with INR monitoring (goal 2–3) (correct answer)

Explanation: Person-centered assessment and treatment planning for DVT anticoagulation consider renal function for dosing and agent selection. The key patient-specific factor is severe CKD (eGFR 28), where DOACs like rivaroxaban and apixaban require adjustment or avoidance. Starting heparin bridge to warfarin is the best choice for safety in advanced CKD, as warfarin is not renally cleared. Rivaroxaban without adjustment risks accumulation; apixaban is dosed correctly but evidence is limited in eGFR <30; enoxaparin requires renal adjustment. In CKD patients, prefer warfarin or adjusted LMWH for anticoagulation. Monitor INR regularly to achieve therapeutic goals.

Question 12

1. Start allopurinol 100 mg daily with titration to urate goal and provide flare prophylaxis with low-dose colchicine (renal-adjusted) (correct answer)
2. Start febuxostat 80 mg daily without prophylaxis because it does not require monitoring
3. Start probenecid 500 mg twice daily because it is preferred in chronic kidney disease
4. Start allopurinol 300 mg daily immediately to rapidly reduce uric acid and avoid future flares

Explanation: Person-centered assessment for gout requires balancing urate-lowering efficacy with renal safety while preventing treatment-induced flares. The key patient-specific factors are chronic tophaceous gout requiring urate-lowering therapy and CKD stage 3b necessitating dose adjustment. Starting allopurinol 100 mg daily with titration and colchicine prophylaxis (choice A) follows guidelines for CKD patients, starting low and titrating to urate goal while preventing mobilization flares. Starting febuxostat at 80 mg (B) without prophylaxis risks severe flares and skips the recommended 40 mg starting dose. Probenecid (C) is contraindicated with eGFR <50 mL/min/1.73m² due to ineffectiveness. Starting allopurinol 300 mg (D) in CKD risks hypersensitivity reactions and should begin at 100 mg or less. The clinical pearl is that allopurinol remains first-line in CKD but requires careful dose titration based on renal function; always provide flare prophylaxis when initiating urate-lowering therapy, adjusting colchicine dose for renal impairment.

Question 13

1. Continue albuterol as needed only; add montelukast 10 mg nightly as sole controller therapy
2. Start low-dose inhaled corticosteroid-formoterol as maintenance and reliever therapy, with inhaler technique counseling (correct answer)
3. Start tiotropium inhaler daily as monotherapy and discontinue albuterol
4. Start prednisone 40 mg daily long-term to prevent exacerbations and eliminate the need for inhalers

Explanation: Person-centered assessment for asthma requires matching controller therapy intensity to disease severity while considering patient preferences and adherence factors. The key patient-specific factor is moderate persistent asthma with frequent symptoms (4 days/week) and reliever use, indicating inadequate control requiring anti-inflammatory therapy. Starting low-dose ICS-formoterol as maintenance and reliever therapy (choice B) provides both anti-inflammatory control and as-needed relief with a single inhaler, improving adherence and outcomes. Montelukast alone (A) is less effective than ICS for persistent asthma and insufficient for moderate disease. Tiotropium monotherapy (C) is not first-line for asthma and discontinuing albuterol removes rescue capability. Long-term oral steroids (D) cause serious adverse effects and are never appropriate for routine asthma control. The clinical pearl is that ICS-formoterol combination as both maintenance and reliever therapy (SMART approach) simplifies regimens, improves adherence, and reduces exacerbations compared to traditional stepped care in moderate persistent asthma.

Question 14

1. Serum uric acid (correct answer)
2. INR
3. Troponin
4. Serum amylase

Explanation: Person-centered assessment and treatment planning for gout involve monitoring uric acid to assess urate-lowering therapy effectiveness. The key patient-specific factor is allopurinol initiation in CKD, where uric acid levels guide dose adjustments. Serum uric acid should be closely monitored for effectiveness, targeting <6 mg/dL to prevent flares. INR is for anticoagulation; troponin for cardiac events; amylase for pancreatitis. In gout management, titrate allopurinol based on uric acid and eGFR. Use prophylaxis like colchicine during initiation to minimize flares.

Question 15

1. Ensure enrollment in a pregnancy prevention program and confirm negative pregnancy testing before and during therapy due to teratogenicity (correct answer)
2. Avoid all dairy products to prevent isotretinoin chelation
3. Co-administer with tetracycline to reduce intracranial pressure risk
4. Monitor INR weekly due to routine anticoagulation interaction in all patients

Explanation: Person-centered assessment and treatment planning for acne with isotretinoin emphasize teratogenicity prevention in females of childbearing potential. The key patient-specific factor is reproductive age, requiring strict pregnancy prevention measures. Ensuring enrollment in a prevention program with testing is the best choice for safety. Avoiding dairy is unnecessary; co-administering tetracycline increases pseudotumor risk; INR monitoring is not routine. In isotretinoin therapy, use iPLEDGE program mandates. Counsel on dual contraception and monthly testing.

Question 16

1. Stop sertraline abruptly and restart at 100 mg when she remembers
2. Recommend taking sertraline with food and using a daily reminder tool (e.g., phone alarm/pillbox); consider dose timing adjustment if nausea persists (correct answer)
3. Double the next sertraline dose after a missed dose to maintain steady state
4. Switch to phenelzine without counseling to avoid dietary restrictions

Explanation: Person-centered assessment and treatment planning for depression focus on improving adherence through side effect management and tools. The key patient-specific factor is nausea and forgetfulness affecting sertraline compliance. Recommending administration with food and reminders is the best choice for adherence without abrupt changes. Abrupt stopping risks withdrawal; doubling doses causes toxicity; switching to phenelzine requires washout and diet restrictions. In antidepressant therapy, use motivational interviewing for adherence. Adjust timing or formulations to minimize GI effects.

Question 17

1. Continue current regimen; add docusate 100 mg PO twice daily for constipation
2. Discontinue diphenhydramine and reassess insomnia using nonpharmacologic strategies; evaluate need for oxybutynin due to anticholinergic burden (correct answer)
3. Increase diphenhydramine to 75 mg nightly to improve sleep maintenance
4. Switch lisinopril to clonidine 0.2 mg PO three times daily to reduce confusion

Explanation: Person-centered assessment and treatment planning in geriatrics focus on reducing anticholinergic burden to minimize cognitive and GI side effects. The key patient-specific factor is confusion and constipation likely due to high anticholinergic load from diphenhydramine and oxybutynin in an elderly patient. Discontinuing diphenhydramine and reassessing oxybutynin is the best choice for safety, as it addresses polypharmacy risks. Adding docusate ignores the root cause; increasing diphenhydramine worsens burden; switching lisinopril to clonidine adds unnecessary risks. In older adults, use tools like Beers Criteria to deprescribe high-risk medications. Promote nonpharmacologic interventions for insomnia and bladder issues.

Question 18

1. Continue azithromycin and citalopram; counsel to take azithromycin with food to prevent nausea
2. Hold albuterol while on azithromycin to reduce tremor risk
3. Address QT-prolongation risk by correcting electrolytes and avoiding/adjusting QT-prolonging agents (e.g., reconsider azithromycin and/or reduce citalopram) (correct answer)
4. Add diphenhydramine at bedtime to prevent azithromycin rash

Explanation: Person-centered assessment and treatment planning in pneumonia therapy require evaluating for drug-induced QT prolongation risks, especially in patients with baseline prolongation. The key patient-specific factor is the history of prolonged QTc, concurrent citalopram use, and electrolyte imbalances, which heighten arrhythmia risk with azithromycin. Addressing QT-prolongation by correcting electrolytes and adjusting QT-prolonging agents is the best choice for safety, as it mitigates torsades de pointes risk. Continuing azithromycin and citalopram without adjustment ignores the interaction; holding albuterol is unnecessary as it doesn't affect QT; adding diphenhydramine is irrelevant for rash prevention. In patients with QT risks, select antibiotics with lower QT potential like beta-lactams. Monitor ECG and electrolytes routinely in high-risk polypharmacy scenarios.

Question 19

1. Increase hydrochlorothiazide to 50 mg PO daily
2. Add lisinopril 10 mg PO daily and recheck potassium and SCr in 1–2 weeks (correct answer)
3. Switch amlodipine to verapamil ER 240 mg PO daily
4. Stop hydrochlorothiazide and start indomethacin 50 mg PO three times daily

Explanation: Person-centered assessment and treatment planning for hypertension involve stepwise addition of agents while monitoring electrolytes and renal function, considering comorbidities like gout. The key patient-specific factor is uncontrolled blood pressure on current therapy and low potassium, where adding an ACE inhibitor addresses both without worsening gout. Adding lisinopril with monitoring is the best choice for effectiveness and safety, as it provides additive BP control and potassium-sparing effects. Increasing hydrochlorothiazide may worsen hypokalemia and gout; switching to verapamil ignores gout risk; stopping hydrochlorothiazide for indomethacin is inappropriate as NSAIDs can elevate BP. In hypertension with gout, prefer non-thiazide options or add agents like ACE inhibitors. Regularly assess electrolytes and renal function post-adjustment to ensure safety.

Question 20

1. Potential methotrexate hepatotoxicity worsened by alcohol; hold methotrexate and address alcohol use and LFT monitoring (correct answer)
2. Folic acid reduces methotrexate efficacy; discontinue folic acid
3. Naproxen is contraindicated with methotrexate at any dose; start ibuprofen instead
4. Elevated LFTs indicate renal failure; reduce methotrexate due to low eGFR

Explanation: Person-centered assessment and treatment planning in rheumatoid arthritis include monitoring for methotrexate toxicity exacerbated by lifestyle factors. The key patient-specific factor is elevated LFTs with alcohol use, indicating potential hepatotoxicity. Holding methotrexate and addressing alcohol is the best choice for safety. Folic acid enhances tolerability, not reduces efficacy; naproxen can be used cautiously; LFT elevation is hepatic, not renal. In methotrexate users, limit alcohol and monitor LFTs regularly. Promote adherence to folic acid and lifestyle modifications.